Observations in APP Bitransgenic Mice Suggest that Diffuse and Compact Plaques Form via Independent Processes in Alzheimer's Disease  by Lord, Anna et al.
The American Journal of Pathology, Vol. 178, No. 5, May 2011
Copyright © 2011 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ajpath.2011.01.052Neurobiology
Observations in APP Bitransgenic Mice Suggest that
Diffuse and Compact Plaques Form via Independent
Processes in Alzheimer’s DiseaseAnna Lord,*† Ola Philipson,* Therése Klingstedt,‡
Gunilla Westermark,§ Per Hammarström,‡
K. Peter R. Nilsson,‡ and Lars N.G. Nilsson*
From the Departments of Public Health and Caring Sciences/
Molecular Geriatrics * and Medical Cell Biology,§ Uppsala
University, Uppsala; Bioarctic Neuroscience AB,† Stockholm; and
Department of Chemistry,‡ IFM, Linköping University, Linköping,
Sweden
Studies of familial Alzheimer’s disease suggest that mis-
folding and aggregation of amyloid- (A) peptides ini-
tiate the pathogenesis. The Arctic mutation of A pre-
cursor protein (APP) results in AD, and Arctic A is
more prone to form A protofibrils and extracellular
deposits. Herein is demonstrated that the burden of
diffuse A deposits but not compact plaques is in-
creased when tg-Swe mice are crossed with tg-ArcSwe
mice synthesizing low levels of Arctic A. The diffuse
deposits in bitransgenic mice, which contain primarily
wild-type A42, accumulate in regions both with and
without transgene expression. However, APP process-
ing, when compared with tg-Swe, remains unchanged
in young bitransgenic mice, whereas wild-type A42
aggregation is accelerated and fibril architecture is al-
tered in vitro and in vivowhen a low level of Arctic A42
is introduced. Thus, the increased number of diffuse
deposits is likely due to physical interactions between
Arctic A and wild-type A42. The selective increase of
a single type of parenchymal A deposit suggests that
different pathways lead to formation of diffuse and
compact plaques. These findings could have general im-
plications for Alzheimer’s disease pathogenesis and par-
ticular relevance to patients heterozygous for the Arctic
APP mutation. Moreover, it further illustrates how A
neuropathologic features can be manipulated in vivo by
mechanisms similar to those originally conceptualized
in prion research. (Am J Pathol 2011, 178:2286–2298; DOI:
10.1016/j.ajpath.2011.01.052)
The cardinal histopathologic lesions in brains affected
with Alzheimer’s disease (AD) are neurofibrillary tangles
2286and extracellular compact plaques. The plaques are
composed of various amyloid- (A) peptides and stain
with amyloid dyes such as Congo red. A is generated
via endoproteolysis of the amyloid precursor protein
(APP). It aggregates and gives rise to compact plaques
with an amyloid core, but also parenchymal diffuse A
deposits and cerebrovascular amyloid angiopathy in ves-
sel walls. Discoveries of point mutations in the APP gene
that caused familial AD provided major insights into the
pathogenesis.1 The Arctic mutation (E693G), located
within the A domain of APP, segregates with clinical
AD.2,3 Because Arctic A (AArc) is more prone to
form protofibrils than is wild-type A (Awt),3,4 this
mutation was used in combination with the Swedish
mutation (KM670/671NL) to develop an animal model
rich in soluble oligomeric A assemblies.5,6 Several
founder lines were generated; however, only the line
with the highest APP expression (line B, Table 1) has
been reported to date.5,7–9 Its neuropathologic pheno-
types were compared in detail with those of a trans-
genic model harboring only the Swedish mutation
(tg-Swe; line A, Table 1).10 In other founder lines of
tg-ArcSwe and tg-Swe, the synthesis of human APP
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undetectable even in very old animals. Herein we
cross-bred a tg-ArcSwe founder line with very scarce
A pathology with a plaque-depositing tg-Swe line, in
which human APP was expressed at a high level. We
deemed that the experiment would be interesting for
the following reasons. First, amyloid formation in hu-
man brain and APP transgenic mice is perceived to be
seeded; that is, rapid fibril formation is thought to be
preceded by a slow and rate-limiting reaction in which
a nucleus is formed.11,12 Both in vitro and in vivo studies
have clearly demonstrated that AArc is more proto-
fibrillogenic than Awt.4,5,13 It was hypothesized that
simultaneous production of AArc and Awt in bitrans-
genic mice would result in a prion-like aggregation
mechanism14 in which the more aggregation-prone
AArc would act as a -sheet template and accelerate
Awt fibrillization. Second, both AArc and Awt are
produced in patients heterozygous for the Arctic mu-
tation, and the pathogenic effects of such a mixture of
A peptides, if any, are unknown. By comparing the
neuropathologic features of bitransgenic mice (tg-Arc-
Swe and tg-Swe) with single transgenic tg-Swe mice,
whether aggregation-prone AArc regulates Awt ag-
gregation and/or formation of amyloid cores in the
brain could be assessed. It was observed that the
mixture of AArc and Awt in bitransgenic mice led to
more A42-immunoreactive (ir) diffuse deposits in ar-
eas with and without transgene expression in bitrans-
genic mice but did not lead to more compact plaques.
These findings suggest that diffuse and compact
plaques develop via independent processes.
Materials and Methods
Transgenic Mice
The expression cassette used to generate transgenic
models and the procedures of genotyping have been
described.5 All mice were kept at the animal facility at
Uppsala University and housed under standard condi-
tions with a 12-hour light/dark cycle and with free access
to food and water. The tg-ArcSwe mice primarily used in
this study were derived from a founder line with a low
level of transgene APP expression. The phenotypes of
this founder line differ markedly from the high-expressor
Table 1. Primary Characteristics of Various APP-Transgenic Line
Model Line
Human APP
expression 
tg-Swe A 6.0
tg-ArcSwe B 2.0
tg-ArcSwe D 0.85
tg-ArcSwe  tg-Swe Bitransgenic 6.85
Nontransgenic 0
*APP expression compared with endogenous murine APP.tg-ArcSwe model.5,10 The various transgenic lines usedin the study are given in Table 1. All mice were genotyped
using PCR with primers located at 1638 to 1655 and 2299
to 2281 in Y00264, followed by digestion with MboII and
separation of bands on 2% agarose gel. The PCR prod-
uct from a tg-ArcSwe mouse was then cleaved into two
bands (456 and 205 bp), that from a tg-Swe mouse into
three bands (364, 205, and 92 bp), and that from a
bitransgenic tg-ArcSwe and tg-Swe mouse harboring
both transgenes into four bands (456, 364, 205, and 92
bp). All mice used in the study were genotyped at age 3
weeks (ear biopsy) and again after death (tail biopsy).
The experiments were approved by an ethical committee
and performed in compliance with national and local
animal care and use guidelines (protocol C223/8). Mice
were anesthetized using 0.4 mL tribromoethanol (Aver-
tin), 25 mg/mL, and intracardially perfused with 0.9%
(w/v) NaCl solution. Brain hemispheres were frozen on
dry ice for biochemical analyses. Alternatively, they were
either directly frozen in metylbutane at 25°C or im-
mersed in 4% paraformaldehyde for 24 hours and used
for immunohistochemical analyses.
Histologic and Image Analyses
Fixed brain tissue was cryoprotected via sequential im-
mersion in 10%, 20%, and 30% (w/v) sucrose for 24
hours. Coronal sections 25-m thick were prepared with
a sledge microtome and stored at 4°C in PBS with 10
mmol/L NaN3. Two sections per individual, approximately
500 m apart (bregma 1.0 mm to 3.0 mm), were
selected for quantitative immunostaining. Fixed tissue
sections were incubated in 25 mmol/L prewarmed citrate
buffer (pH 7.3) for 5 minutes at 85°C, rinsed in deionized
water, and immersed in 70% formic acid for 5 minutes.
Endogenous peroxidase activity was quenched with
0.3% dH2O2 in Dako block (DakoCytomation, Glostrup,
Denmark) for 15 minutes, and sections were permeabil-
ized with 0.4% Triton X-100. The sections were incubated
with 1 g/mL polyclonal A40- or A42-specific antibod-
ies,15 monoclonal AArc-specific antibodies (mab27 at 1
g/mL9), 0.5 g/mL N-terminal A antibody 6E10 (Cova-
nce, Princeton, NJ) or 82E1 (IBL International GmbH,
Hamburg, Germany), 0.2 g/mL goat anti-mouse popro-
tein J (AF2747; R&D Systems, Inc., Minneapolis, MN),
goat anti-apolipoprotein E (ApoE) (AB947, diluted
1:5000; Chemicon International Inc., Temecula, CA), or
rine APP
ression  APP overexpression*
Age at onset
of plaque
deposition
(months)
1 Sevenfold APPSwe 12
1 Threefold APPArcSwe 5–6
1 Twofold APPArcSwe 18
1 Eightfold APP
(APPArcSwe  APPSwe)
12
1s
Mu
exp0.5 g/mL monoclonal anti-human heparan sulfate
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scott, MA) in PBS-buffered saline solution with 0.1%
Tween 20 at 4°C overnight. Biotinylated goat anti-rabbit,
goat anti-mouse, or rabbit anti-goat antibodies (Vector
Laboratories, Inc., Burlingame, CA) were applied for 30
minutes at room temperature. Sections were then incu-
bated with streptavidin-coupled horseradish peroxidase
(Mabtech AB, Nacka Strand, Sweden) for 30 minutes and
developed using the Nova Red chromogen kit (Vector
Laboratories, Inc.). For double staining with the A42-
specific antibody and either thioflavine T (ThT) or the
luminescent conjugated oligothiophene (LCO) p-FTAA,
the sections were treated as described, and a fluorescent
secondary antibody [Alexa Fluor 594 goat anti-rabbit (In-
vitrogen Corp., Carlsbad, CA)] diluted 1:250 in PBS was
used to visualize the A immunostaining. The sections
were washed in PBS and incubated with 3 mol/L p-
FTAA16 in PBS or with 0.2% (w/v) ThT (Sigma-Aldrich
Corp., St. Louis, MO) in PBS for 30 minutes with shaking
at room temperature. After rinsing with PBS, the sections
were washed in dH2O and mounted with Vectashield
(Vector Laboratories, Inc.). Compact plaques were de-
tected using Congo red (Sigma-Aldrich Corp.) as pre-
viously described.17 The burden of diffuse and com-
pact deposits in the cerebral cortex was measured in
two image fields per section at 20 magnification.
Images were captured using a Nikon microscope
(DXM1200F; Nikon Instruments Inc., Melville, NY)
equipped with a digital camera, converted to gray
scale, and segmented with an autothreshold command
(Image Pro-Plus; MediaCybernetics, Silver Spring,
MD). Custom macros were used to measure the
stained area of interest as a percentage of the total
area.
p-FTAA and Fluorescence Microscopy
Frozen brain sections 10-m thick from 18-month-old
tg-ArcSwe (line B), tg-Swe (line A), and bitransgenic tg-
ArcSwe (line D) and tg-Swe (line A) mice were fixed in
absolute ethanol for 10 minutes and rehydrated in 50%
ethanol followed by water. The sections were incubated
in PBS for 10 minutes and stained with 3 mol/L p-
FTAA16 in PBS for 30 minutes at room temperature. After
rinsing with PBS, the sections were mounted with Dako
fluorescence mounting medium (DakoCytomation A/S).
The medium was allowed to solidify for 3 hours before the
slide rims were sealed with nail polish. Spectra and fluo-
rescence images were obtained using a fluorescence
microscope (Zeiss Axioplan; Carl Zeiss Ltd., Jena, Ger-
many) equipped with a SpectraCube (optical head) mod-
ule (Applied Spectral Imaging, Ltd., Migdal Ha’Emek,
Israel) using bandpass filters 405/30 (LP450), 470/40
(LP515), and 546/12 (LP590). p-FTAA bound to compact
plaques (10 plaques per animal, three animals from each
group) was excited at 405 and 546 nm. SpectraView 3.0
EXPO software (Applied Spectral Imaging, Ltd.) was
used to merge the information from the double excitation
and create full visible-light emission spectra (450 to 700
nm) for p-FTAA when combining those excitation wave-
lengths. Fluorescent spectral unmixing, which is a func-tion within the program, was performed to separate the
emitted light intensities according to wavelength. The
emission spectrum for p-FTAA bound to compact
plaques in tg-ArcSwe (line B) was used to define red
emission, and the emission spectrum for p-FTAA bound
to compact plaques in tg-Swe (line A) was used to define
green emission. By performing spectral unmixing, the
fraction of each defined spectrum could be determined
for each compact plaque found in tg-ArcSwe (line B),
tg-Swe (line A), and bitransgenic mice, respectively.
SDS-PAGE and Western Blot Analysis
For analysis of A, multiphasic urea/SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and Western blot anal-
ysis were performed. This gel system enables differenti-
ation of A of various lengths and also Awt and AArc.
Samples were subjected to electrophoresis using a 15%
T, 5% C bicine-Tris separation gel [T, total concentration
of acrylamide; C, bis-acrylamide cross-linker content
(acrylamide/bis-acrylamide, 40%; Sigma-Aldrich Corp.)]
containing 8 mol/L urea. They were run at 24 mA, 30 V.
Gels and buffers have been described previously,18,19
with the distinction that in the present study, 8 mol/L urea
was included in the stacking gel. For analysis of total
brain A, tissues at bregma 1.0 mm to 3.0 mm were
used. Tissue sections (30 m; bregma 1.0 mm to 0.1
mm) were dissected and analyzed for A levels in stria-
tum and cerebral cortex. Brain tissue was homogenized
in a final concentration of 70% formic acid at a ratio of
1:10 (w/v) using a Dounce homogenizer, sonicated for 30
seconds, and centrifuged at 100,000g at 4°C for 60 min-
utes. The supernatants were stored at80°C before they
were analyzed with enzyme-linked immunosorbent assay
(ELISA) and SDS-PAGE Western blot analysis. For anal-
ysis of APP levels, brain tissues (bregma 1.0 mm to
3.0 mm) from 2-month-old mice were homogenized in
Tris-buffered saline solution [20 mmol/L Tris and 137
mmol/L NaCl (pH 7.6)] supplemented with 2% (w/v) SDS
and complete protease inhibitor (Hoffman-La Roche AG,
Basel, Switzerland), sonicated for 30 seconds, and cen-
trifuged at 100,000g at 4°C for 60 minutes. Proteins in the
supernatant were separated on 4% to 20% Tris-tricine
gels (Invitrogen Corp.). Protein transfer and Western blot
analysis were performed as previously described.5
A Enzyme-Linked Immunosorbent Assay
Ninety-six–well plates were coated for 12 hours at 4°C
with antibodies specific for A40 or A42 (200 ng per
well) and used for measuring A1-40 or A1-42 levels.
For the total A assay, plates were coated with 100 ng
per well of the N-terminal A-specific antibody 82E1 (IBL
International GmbH) in PBS [130 mmol/L NaCl, 7 mmol/L
NaH2PO4, and 3 mmol/L Na2HPO4 (pH 7.4)] and blocked
with 1% bovine serum albumin in phosphate-buffered
NaCl, 0.15% Kathon (Rohm and Haas Co., Philadelphia,
PA). Formic acid extracts of mouse brain were neutral-
ized in 1 mol/L Tris (pH 10) and diluted in ELISA incuba-
tion buffer (PBS with 0.1% bovine serum albumin, 0.05%
Tween 20). Samples or standards (recombinant wt/Arctic
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incubated for 2 hours at room temperature. Biotinylated
mAb27, 0.5 g/mL, with an epitope in the mid-domain of
Arctic A,9 was used to measure total AArc. Biotinylated
4G8, 0.5 g/mL (Covance, Inc.), was used to detect total
A, and biotinylated mAb1C3, 0.5 g/mL,7 was used to
quantify A1-40 or A1-42. Both biotinylated detection
antibodies and streptavidin-coupled horseradish peroxi-
dase (Mabtech AB), diluted 1:2000, were incubated for 1
hour in successive steps. K-blue aqueous (ANL-Produk-
ter AB, älvsjö, Sweden) was used as horseradish perox-
idase substrate, the reaction was stopped using 1 mol/L
H2SO4, and the optical density was measured at 450 nm
with a spectrophotometer (SpectraMax 190; Molecular
Devices, Inc., Sunnyvale, CA). Wells were washed three
times between each step in ELISA washing buffer (phos-
phate-buffered NaCl with 0.1% Tween 20 and 0.15%
Kathon).
mAb158 Protofibril/Oligomer ELISA
The mAb158 ELISA7 detects oligomers larger than 100
kDa, which is consistent with the original description of
oligomeric assemblies of A.20 In brief, each well in 96-
well plates was coated with 200 ng mAb158 in PBS
overnight at 4°C and blocked with 1% bovine serum
albumin. The samples were centrifuged at 17,900  g for
5 minutes before incubation to ensure that they were
devoid of any insoluble A aggregates. Samples were
added to plates in duplicate and incubated for 2 hours at
room temperature. Biotinylated mAb158, 0.5 g/mL, was
added and incubated for 1 hour at room temperature,
followed by incubation with streptaviden-coupled horse-
radish peroxidase for 1 hour at room temperature. K-blue
aqueous (ANL-Produkter AB) horseradish peroxidase
substrate was used, and the reaction was stopped using
1 mol/L H2SO4. After the blocking step, plates were
washed three times between each step. All samples and
antibodies were diluted in ELISA incubation buffer (PBS
with 0.1% bovine serum albumin and 0.02% Tween 20).
The standard was generated by incubating A1-42wt
(American Peptide Co., Inc., Sunnyvale, CA) in 50 mol/L
PBS for 30 minutes at 37°C, followed by centrifugation at
16,000 g for 5 minutes. The supernatant was loaded on
a Superdex 75 10/300 GL column, resulting in a single
high-molecular-weight peak, which was collected.
Kinetic Measurement of A Fibrillation
Recombinant A1-42wt and A1-42Arc (American Pep-
tide Co., Inc.) were treated with 100% hexafluoroisopro-
panol (Sigma-Aldrich Corp.), reaching a final concentra-
tion of 1 mmol/L. Hexafluoroisopropanol was allowed to
evaporate in a chemical fume hood, and A was then
solubilized as a 400-mol/L stock solution in 10 mmol/L
NaOH and stored at 80°C. Immediately before use,
A1-42wt and A1-42Arc were diluted in PBS [50 mmol/L
phosphate buffer and 100 mmol/L NaCl (pH 7.4)] to 20
mol/L and added to wells of a nonbinding 96-well mi-
crotiter plate (Greiner Bio-One GmbH, Frickenhausen,
Germany). ThT (Sigma Corp.) and p-FTAA16 were pre-pared as 15-mol/L stock solutions in PBS (pH 7.4) and
added to the wells at a final concentration of 1.2 mol/L.
Plates were incubated at room temperature for up to 22
hours under agitation. A aggregation was recorded with
a fluorometer (Wallac Victor 2 multilabel counter; Perkin
Elmer Inc., Waltham, MA) as described for ThT21 and
p-FTAA.16 The wavelengths of excitation and emission
were 440 and 485 nm, respectively. Experiments were
performed in triplicate, and fluorescence from free ThT or
p-FTAA, incubated without A in parallel, was subtracted
from the readings.
Electron Microscopy
The ultrastructure of A aggregates was examined by
collecting samples of A-solutions, 20 mol/L, from the
kinetic experiment. Solutions of A were diluted to 1
mol/L in mH2O and spotted on grids coated with car-
bon-formvar. Excess fluid was removed after 30 seconds,
and 2.5% uranyl acetate, 5 to 10 L, was added to the
grids, and again excess fluid was quickly removed. The
negatively stained specimen were examined and photo-
graphed using an electron microscope (JEOL 1230;
JEOL Ltd., Tokyo, Japan) at 100 kV.
Statistical Analyses
Data were analyzed using the Student’s t-test or with one-
or two-way analysis of variance followed by Tukey’s mul-
tiple comparison post hoc test (GraphPad Software, Inc.,
San Diego, CA). Results were presented as values rep-
resenting the group mean and standard error of the mean
(SEM). The relationship between A40-ir and A42-ir bur-
den was investigated using linear regression, and slopes
were compared using the F-test. P  0.05, P  0.01, and
P  0.001 were considered significant.
Results
Transgene Expression in Founder Lines of
Tg-Swe and Tg-ArcSwe Mice
Intraneuronal A accumulates in young tg-ArcSwe
mice, and extracellular deposition of compact plaques
begins at age 5 to 6 months, whereas the frequency of
diffuse A deposits remains extremely low.5 This high-
expressing founder line, with threefold APP expression
compared with the level of murine APP, is hereafter
referred to as tg-ArcSwe line B. In tg-Swe line A, here-
after referred to as tg-Swe, APP expression is seven-
fold higher than in nontransgenic mice, and extracel-
lular A deposition emerges at approximately 12
months of age.10 Several additional founder lines of
tg-ArcSwe with lower transgene expression were gen-
erated. It is not known whether a small amount of highly
aggregation-prone peptides such as AArc can influ-
ence the comparably slower aggregation of Awt. To
investigate this, tg-Swe mice were crossed with tg-Arc-
Swe (line D), which express human APPArcSwe at a low
level (total APP is less than twofold compared with murine
2290 Lord et al
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human plus murine, in 2-month-old mice was analyzed us-
ing Western blot analysis. Human APP was sevenfold more
abundant in young tg-Swe than in age-matched tg-ArcSwe
(line D) as measured at densitometry. For comparison, a
tg-ArcSwe mouse (line B)5 with threefold APP expression
and a nontransgenic mouse were included in the analyses
(Figure 1B; Table 1). In tg-Swe, with sevenfold APP expres-
sion, an abundance of human APP was observed in the hip-
pocampal pyramidal cell layers CA1 and CA3, in the lower
layers of cerebral cortex, and to some extent in the upper
cortical lamina (Figure 1, C and F). The anatomical dis-
tribution was similar in tg-ArcSwe (line D), although the
laminar expression pattern in the cerebral cortex was
attenuated (Figure 1, D and G). As expected, in a non-
transgenic mouse, only a faint nonspecific background
signal was observed (Figure 1, E and H).
Burden of Compact Plaques in Tg-Swe Is Not
Altered by a Minute Amount of AArc
Whether AArc, at a level that seemed insufficient on
Figure 1. High-level APP-expressing tg-Swe mice (line A) produced seven
times more human APP than did tg-ArcSwe mice (line D). A: Experimental
design of the study is schematically illustrated. B: APP protein synthesis of
transgenic models, tg-Swe (line A), and nontransgenic mice, tg-ArcSwe (lines B
and D), was analyzed using Western blot analysis and antibodies 6E10 (human
APP), 22C11 (human plus endogenous APP), and -actin. Anatomical distribu-
tion of human APP detected with 6E10-immunostaining in 2-month-old tg-Swe,
line A (C and F), low-expressing founder line of tg-ArcSwe, line D (D and G),
and a nontransgenic mouse (E and H). Scale bars  1 mm.its own to generate extracellular A deposition, couldinstigate or modify the neuropathologic conditions pro-
duced by an excess of Awt was investigated. There-
fore, tg-ArcSwe (line D) and tg-Swe were crossed, and
the neuropathologic features of bitransgenic mice were
compared with those of singly tg-Swe mice. The neu-
ropathologic conditions of singly tg-ArcSwe (line D)
mice were reassessed in two aged individuals gener-
ated from the cross-breeding experiment at the study
end point (ie, 18-month-old mice). Six tissue sections
distributed along the rostrocaudal axis of the brain
were stained with different A-antibodies (6E10, 82E1,
and A42-specific). In one of the 18-month-old mice, a
single plaque was observed, and in the other mouse,
three A-immunopositive plaques were observed in six
tissue sections altogether. Thus, A deposition and
intraneuronal A immunostaining in aged tg-ArcSwe
(line D) was limited. Biochemical analyses confirmed
that age-dependent A accumulation was modest. The
mean (SEM) level of A1-40 was 9.9 (1.2) pmol/g (n 
2) at 2 months, and 19.5 (1.7) pmol/g at 18 months (n  2)
in tg-ArcSwe (line D). This was in contrast to findings in
11-month-old tg-ArcSwe (line B, n  2) with a cortical
A-burden of 2.5% (0.3%), total A1-40 levels of 8982
(770) pmol/g, and strong intraneuronal A immuno-
staining (see Supplemental Figure S1 at http://ajp.
amjpathol.org). These results were not surprising be-
cause it is well known that A deposition will occur only
if a sufficiently high level of A synthesis is attained
and that age at onset depends on the level of trans-
gene expression.22 If the effect of transgenes on
pathologic features were simply additive, bitransgenic
mice, tg-ArcSwe (line D) and tg-Swe, and singly tg-
Swe would be expected to exhibit essentially the same
type and quantity of A deposits.
Brains from bitransgenic and tg-Swe mice were first
examined with Congo red and an A40-specific anti-
body. Both of these markers are associated with com-
pact plaques in tg-Swe. At age 12 months, A40 bur-
den was not higher in bitransgenic mice [mean (SEM),
1.2% (0.3%); n  17] than in tg-Swe [1.0% (0.2%); n 
16; P  0.55; Figure 2, A–C]. Likewise, Congo red
burden was not increased in bitransgenic mice [0.25%
(0.09%); n  17] compared with singly tg-Swe [0.19%
(0.07%); n  16; P  0.57; see Supplemental Figure
S2, A–C, at http://ajp.amjpathol.org]. At age 18 months,
again A40-ir burden was not higher in bitransgenic
compared with tg-Swe mice [3.6% (0.6%); n  7, and
2.8% (0.6%); n  8; P  0.43; Figure 2C]. Likewise,
Congo red burden was not elevated in bitransgenic
mice [1.3% (0.6%); n  7] compared with age-
matched tg-Swe [1.0% (0.3%); n  8; P  0.61; see
Supplemental Figure S2C at http://ajp.amjpathol.org].
Sections were then stained using an LCO, p-FTAA,16 a
conformational-dependent probe with a flexible struc-
ture that can serve as an optical tool to reveal heteroge-
neity among A and prion deposits in a manner similar to
luminescent conjugated polythiophenes.10,23,24 As ex-
pected from previous imaging experiments using Dro-
sophila models,25 the p-FTAA emission spectrum of com-
pact plaques in tg-ArcSwe (line B; Figure 2D) and tg-Swe
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compact plaques in bitransgenic mice (Figure 2F) resem-
bled that in tg-Swe; however, small areas within the de-
posits were more similar to compact plaques in tg-Arc-
Swe (line B). Spectral analyses of emitted fluorescence
from multiple individual compact plaques confirmed that
signals in bitransgenic mice were intermediate to those of
compact plaques in tg-ArcSwe and tg-Swe (Figure 2, G
and H). Thus, a minute amount of AArc in bitransgenic
mice did not influence burden of compact plaques, but
did result in a different LCO spectral profile in individual
compact plaques.
Increased Accumulation of Diffuse
A42-Immunoreactive Deposits in
Bitransgenic Mice
Tissue sections were immunostained with an A42-spe-
cific antibody, which in brains affected with AD typically
detects both compact plaques and diffuse A deposits,
although diffuse A deposits are rarely observed in tg-
Figure 2. AArc did not change A40 burden but influenced p-FTAA fluo-
rescence of individual compact plaques in bitransgenic mice. Representative
12-month-old bitransgenic (A) and singly tg-Swe (B) mice. C: There was no
statistically significant difference in cortical A40-burden between 12- and
18-month-old bitransgenic and singly tg-Swe mice. Fluorescence images of
p-FTAA bound to compact plaques and excited at 470 and 546 nm. Images
illustrate a variation in p-FTAA emission spectrum between compact plaques
found in tg-ArcSwe, line B (D), singly tg-Swe (E), and bitransgenic mice (F),
respectively. The resulting emission when the excitation wavelengths (470
and 546 nm) are separated into two channels is shown below. Spectral
unmixing of p-FTAA emission when bound to compact plaques in bitrans-
genic mice revealed a shift toward that of compact plaques in tg-ArcSwe
compared with singly tg-Swe. G and H, Fraction of red spectrum of 10
individual plaques from three animals in each group (filled and open boxes
and diamonds). Scale bars: 500 m (B); 30 m (D–F).Swe. At age 12 months, the mean (SEM) burden ofA42-ir plaques was more than fourfold higher in bitrans-
genic mice [4.1% (0.9%); n  17] than in tg-Swe [0.9%
(0.3%); n  16; P  0.01 Figure 3, A, D, and G]. In
18-month-old mice, A42 burden was still increased
more than threefold in bitransgenic mice [9.9% (1.3%); n
 7] compared with tg-Swe mice [3.1% (0.8%); n 8; P
0.001; Figure 3, B, E, and G]. Groups of bitransgenic (r 
0.86; P 0.0001) and tg-Swe mice (r 0.90; P 0.0001)
fitted well into separate linear regression models when
A40 burden was plotted against A42 burden for each
animal. The slope of linear regression for bitransgenic mice
[2.3 (0.3)] and tg-Swe mice differed [1.1 (0.1); F1,44 14.8;
P  0.001]. Thus, introduction of a small amount of AArc,
produced by low expression of the tg-ArcSwe transgene,
strongly and selectively increased the burden of diffuse
A42-immunopositive deposits (Figure 3H). Next, consec-
utive sections were stained to investigate which A pep-
tides were located in diffuse and compact plaques. A42,
A40, AArc, and Congo red staining co-localized in com-
pact plaques in bitransgenic mice. There was an addi-
tional population of diffuse A42-ir deposits in the ce-
rebral cortex in these mice, but also in the striatum,
where there is essentially no transgene expression
Figure 3. AArc favored an increased A42-burden in bitransgenic mice. A
burden in the cerebral cortex of 12-month-old (A and D) and 18-month-old
(B, C, E, and F) bitransgenic (A–C) and singly tg-Swe (D–F) mice. A42
burden in representative 12-month-old (A) and 18-month-old (B) bitrans-
genic mice and in 12-month-old (D) and 18-month-old (E) tg-Swe. A40
burden is shown from semiadjacent sections of 18-month-old bitransgenic
(C) and tg-Swe (F) mice. G: A42 burden was investigated in all animals
using quantitative image analysis. H: There was a linear correlation between
A40 burden and A42 burden among individuals within the experimental
groups, but a substantial difference between bitransgenic and singly tg-Swe
mice. Scale bar  900 m.
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silver intensification of Ni-DAB product,26 nor using
unfixed tissue section and a 10-fold higher concentra-
tion of mAb279 resulted in staining of the diffuse de-
posits with the AArc antibody (data not shown). In
tg-Swe, A40, A42, and Congo red staining were
most often co-localized, and the compact plaques, as
expected, did not stain with an AArc antibody (Figure
4, E–H and M–P). It is important to note that the selectivity
of the AArc-specific antibody, mAb27, depends on a
unique conformation around glycine 22 and not on the lin-
ear amino acid sequence. Thus, mAb27 is selective for
AArc at ELISA analysis but not, for example, at denaturing
Figure 4. Increased A42 burden in bitransgenic mice was due to diffuse d
in 18-month-old bitransgenic (A–D and I–L) and singly tg-Swe mice (E–H and
(A, E, I, and M), AArc-specific antibody (B, F, J, and N), Congo red (C, G, K
areas shown at higher magnification (I and M, respectively), and arrows in
m (I–P). The spots in (F) are unspecific staining that are due to slight damWestern blot analysis.9 The selectivity of mAb27 immuno-staining was determined using tissue sections from plaque-
bearing tg-ArcSwe, line B (positive control) and tg-Swe
(negative control) mice that were prepared and stained in
parallel to those from bitransgenic mice.
Factors were then searched that could further
explain how diffuse and compact plaques could form
via independent processes. ApoE resides in extracel-
lular deposits and regulates A deposition in vivo.27
Other plaque-associated factors such as apolipopro-
tein J and heparan sulfate selectively affect burden of
compact plaques.28,29 Therefore, we searched for se-
lective markers of diffuse deposits and compact
plaques. Among those, only heparan sulfate was spe-
that were not recognized by an antibody specific for AArc. A-deposition
Adjacent sections (10 m) were immunostained with A42-specific antibody
), and A40-specific antibody (D, H, L, and P). Arrows in A and E indicate
e some diffuse A42-immunoreactive deposits. Scale bars: 1 mm (A–H); 200
parts of this tissue section.eposits
M–P).
, and Ocifically associated with compact plaques, whereas
Selective Increase in Diffuse A Plaques 2293
AJP May 2011, Vol. 178, No. 5ApoE and apolipoprotein J were found in both diffuse
and compact plaques (see Supplemental Figure S3 at
http://ajp.amjpathol.org).
AArc Facilitates Striatal A1-42wt
Accumulation and Formation of Diffuse Deposits
A deposition in bitransgenic and tg-Swe mice was bio-
chemically analyzed using urea/SDS-PAGE and Western
blot analysis. Extracts of 70% formic acid (total A) from
bitransgenic and tg-Swe mouse brain with early- and
late-stage plaque (ages 12 and 18 months) were inves-
tigated. The system was calibrated with synthetic A
peptides (lanes 1 to 4, Figure 5A), and a 6-month-old
tg-ArcSwe (line B) with high level of APP expression was
used as reference material (lane 7).10 In 18-month-old
bitransgenic mice, A1-38wt, A1-40wt, and A1-42wt
were predominant, with low levels of AArc (A1-40Arc
and/or A1-42Arc) (lane 5, Figure 5A). These A species
were present at 12 months in bitransgenic mice (lane 8),
although the levels of all A species were much lower
and A1-40wt was the predominant species. As ex-
pected, high levels of A1-40wt were observed in 18-
month-old tg-Swe, and A1-38wt and A1-42wt were
also detected (lane 6). Brain tissue from a tg-ArcSwe line
B mouse with plaque deposition contained AArc pep-
tides, primarily A1-40Arc and A1-42Arc and presum-ably A1-38Arc (lane 7), as previously described.10 An
immunohistochemical and a biochemical technique were
combined to further determine the identity of A in the
diffuse deposits in bitransgenic mice. In thin tissue sec-
tions, the striatum, which contained only diffuse A de-
posits, was separated from the cerebral cortex, in which
both diffuse and compact deposits were observed (Fig-
ure 5B). Extracts of 70% formic acid in striatal and cere-
bral cortical tissue (layers I to VI) from a representative
18-month-old bitransgenic mouse were analyzed using
urea/SDS-PAGE. There was a marked region-specific dif-
ference, with A1-42wt as the predominant A peptide in
the striatum, whereas A1-42wt and A1-40wt with some
A1-38wt were present in the cerebral cortex (Figure 5C).
Because the sensitivity of SDS-PAGE and Western blot
analysis is somewhat limited, ELISA was used to measure
AArc levels (82E1/mAb27 sandwich) and total A levels
(82E1/4G8 sandwich) in the cerebral cortex and striatum.
The mean (SEM) levels of AArc and total A in cerebral
cortex were 160 (24) pmol/g and 2300 (190) pmol/g (n 
4), respectively; that is, approximately 7% of total A was
AArc. In the striatum, the levels of AArc and total A
were 16 (4) pmol/g and 770 (50) pmol/g, respectively
(n  4); that is, 2% of total A was AArc (Figure 5D).
These findings suggest that AArc/APP facilitates formation
of diffuse A deposits, which consist primarily of A1-42wt
Figure 5. AArc led to increased accumulation of
A42wt and more diffuse deposits in the striatum
in bitransgenic mice. Urea/SDS-PAGE andWestern
blot analysis (with 6E10 antibody) of extracts of
70% formic acid (total A) of plaque-bearing bi-
transgenic and tg-Swe mice at ages 12 and 18
months. A: For comparison, tissue from a 6-month-
old tg-ArcSwe (line B; high-expressor line) with
plaques and synthetic A peptides were included
in the experiments. B: Immunostaining of a brain
section from an 18-month-old bitransgenic mouse
with an A42-specific antibody before and after the
striatum (caudate putamen) had been dissected.
Extracts of 70% formic acid from dissected striatum
(caudate putamen) and cerebral cortex layers I to
VI in an 18-month-old bitransgenic mouse at the
level of the frontal cortex (bregma 1.0 mm to 0.1
mm). C: Localization of A peptides differed mark-
edly, and A1-42wt was the predominant A pep-
tide in the striatum, whereas both A1-40wt and
A1-42wt were abundant in the cerebral cortex.D:
Further analyses of the same formic acid extracts of
dissected tissues at ELISA (pmol/g tissue) demon-
strated that AArc was present but represented
only a small fraction of total A in both cerebral
cortex and striatum (n  4). Scale bars: 1 mm (B);
100 m in enlarged images.and possibly small amounts of AArc. In old (age 24
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its were also observed in areas both with and without
transgene expression, for example, in the striatum (see
Supplemental Figure S4 at http://ajp.amjpathol.org). Thus,
AArc strongly facilitated a process whereby diffuse de-
posits formed. It did not create a unique process of A
aggregation that does not normally occur in tg-Swe mice.
APPArcSwe Does Not Alter APPSwe
Processing in Bitransgenic Mice
APPArcSwe could possibly interact with APPSwe and,
thereby, quantitatively or qualitatively influence its endo-
proteolysis, for example, through APP dimerization.30
This could explain different A neuropathologic features
in aged bitransgenic and tg-Swe mice. If so, alterations in
the steady-state level of A would be expected in young
bitransgenic mice without extracellular A deposition.
The total A level tended to be higher in formic acid
extracts from brains of 2-month-old bitransgenic mice
[mean (SEM), 8.0 (0.5) pmol/g A1-40 and 6.7 (0.3)
pmol/g A1-42; n  5] compared with age-matched tg-
Swe [7.0 (0.6) pmol/g A1-40; P  0.28, and 6.0 (0.3)
pmol/g A1-42; n  6; P  0.14] (see Supplemental
Figure S5A at http://ajp.amjpathol.org); however, the
A42/A40 ratio in the bitransgenic mice [0.84 (0.04)]
and tg-Swe [0.85 (0.04)] did not differ (P  0.75) (see
Supplemental Figure S5B at http://ajp.amjpathol.org).
When a total AArc ELISA (A1-xArc) was used, the level
of AArc in bitransgenic mice was 1.60 (0.20) pmol/g (n 
5), and, as expected, was not detectable in tg-Swe (n  5)
(see Supplemental Figure S5C at http://ajp.amjpathol.
org). Thus, total A levels were higher in young bitrans-
genic mice than in age-matched tg-Swe mice; how-
ever, this increase was not more than what would be
expected by the increased transgene expression (ie,
the additional approximately one-eighth processing of
APPArcSwe and AArc synthesis in bitransgenic
mice). Thus, it was concluded that APPArcSwe did not
selectively increase A1-42wt synthesis from the
APPSwe transgene in bitransgenic mice.
AArc Facilitates Formation of Prefibrillar and
Fibrillar Assemblies of Awt in Vitro
The increased levels of diffuse deposits in bitransgenic
mice could perhaps be explained by the ability of AArc
to facilitate refolding and aggregation of Awt. To inves-
tigate this, an in vitro system was designed to evaluate the
influence of A1-42Arc on A1-42wt aggregation. LCOs
enable staining and analysis of prefibrillar A assem-
blies.16 Thus, the fluorescence of an LCO, p-FTAA, was
used as a readout of prefibrillar A aggregates, and that
of ThT was used as a measure of amyloid fibril formation.
Recombinant A1-42wt and A1-42Arc were treated with
hexafluoroisopropanol to dissociate possible preformed
A aggregates that could seed fibril formation. The mo-
nomeric A peptides were allowed to form fibrils, and the
kinetics was monitored with ThT (Figure 6A) and p-FTAA
(Figure 6B). A1-42wt and A1-42Arc were incubatedeither alone or together in ratios of 7:1 or 1:1 (Awt/
AArc). The total concentration of A (ie, A1-42wt
and/or A1-42Arc either alone or in combination) was
always 20 mol/L. A lag phase was followed by an ex-
ponential growth phase and then a plateau phase. With
both ThT and p-FTAA, the lag phase was shorter when
A1-42wt and A1-42Arc were mixed before polymeriza-
tion, at 7:1 or 1:1. The effect seemed to depend on the
presence of AArc but not on the percentages of AArc
and Awt. When mixing A1-42wt and A1-42Arc, the
intensity of ThT fluorescence was noticeably lower in the
plateau phase; however, this was not observed when
using p-FTAA. The ultrastructure of in vitro preparations
was then investigated. The starting material for all sam-
ples contained only small aggregates but no fibrils
(Figure 6, C–E). An almost evenly distributed carpet of
Figure 6. A mixture of AArc and Awt accelerated prefibrillar A aggre-
gate formation in vitro. Aggregation of recombinant A1–42 was monitored
with ThT (A) and p-FTAA (B). Fibrillation kinetics of A1-42wt (open
circles; 20 mol/L), A1-42wt and A1-42Arc in a ratio of 7:1 (open
triangles; 20 mol/L total A), A1-42wt and A1-42Arc in a ratio of 1:1
(solid triangles; 20 mol/L total A), and A1-42Arc (solid circles; 20
mol/L). p-FTAA detects early events in the aggregation process.16 With both
probes, the lag phase was shorter when AArc was present. Each symbol
represents the mean (SEM) of two or three experiments. Ultrastructural
analysis of A aggregates at electron microscopy. Samples of A1-42Arc (20
mol/L; C, F, and I), A1-42wt and A1-42Arc at a ratio of 7:1 (20 mol/L
total A; D, G, and J), and A1-42wt (20 mol/L; E, H, and K) were analyzed
at 0 minutes (C–E), 100 minutes (F–H), and 1200 minutes (I–K). Scale bars:
100 nm (C–K).proteins was present at time 0 when A1-42wt and A1-
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p-FTAA-fluorescence was increased, small clusters of
thin fibrils were observed in samples consisting only of
A1-42Arc (Figure 6F), whereas a few fibrillar aggregates
with varying morphologic appearance were present at
100 minutes when A1-42wt and A1-42Arc were mixed
(7:1; Figure 6G). In contrast, in samples that contained
only A1-42wt peptide, p-FTAA fluorescence intensity
was low (Figure 6B), and both fibrils and low-molecular-
weight aggregates were rare at this time point (Figure
6H). At 1200 minutes, incubation of A1-42Arc alone
gave rise to an abundance of tightly aggregated thin
fibrils (Figure 6I). In contrast, mixtures of A1-42wt and
A1-42Arc contained large numbers of massive fibrillar
aggregates. These mixtures of peptides formed thin fi-
brils that seemed to be composed of globular subunits
(Figure 6J). Their appearance was different from the
straighter fibrils observed with A1-42wt (Figure 6K).
Analyses of A Protofibrils, p-FTAA Staining,
and A42-Immunoreactivity in Bitransgenic
Mice
Staining with ThT or p-FTAA was combined with A IHC
on paraformaldehyde-fixed sections. Many but not all
diffuse A42-immunoreactive deposits in the cerebral
cortex and striatum were also stained using p-FTAA in an
18-month-old bitransgenic mouse (Figure 7, A, C–H). In
contrast, there was no overlap between ThT staining and
A42 immunoreactivity in the striatum of bitransgenic
mice (see Supplemental Figure S6 at http://ajp.amjpathol.
org). The same results were observed when thioflavine S
Figure 7. Diffuse A deposits in bitransgenic mice were stained using
p-FTAA. Tissue sections 25 m thick from a bitransgenic mouse were fixed
in paraformaldehyde and stained with an A42-specific antibody together
with either p-FTAA (A) or ThT (B). The area at the tip of the open arrow in
A is magnified (C–E), and the area at the tip of the solid arrow in B is
enlarged (F–H). Both dyes enabled visualization of compact plaques, and
p-FTAA also stained numerous diffuse A deposits (F–H). Scale bars: 1 mm
(A and B); 100 m (C–H).was used instead of ThT (data not shown). Moreover, Aprotofibrils, which are large soluble A oligomers, were
more abundant in Tris-buffered saline solution extracts in
12-month-old bitransgenic tg-ArcSwe and tg-Swe [mean
(SEM), 163 (20) pmol/L; n  11] than in age-matched
tg-Swe [83 (13) pmol/L; n  9; P  0.01].
Discussion
Enhanced deposition of small and diffuse A42-immuno-
positive deposits were observed in regions with and with-
out transgene expression in bitransgenic mice producing
both Awt and AArc. In contrast, the burden of compact
plaques was similar in bitransgenic and singly tg-Swe
mice. Transgenic mice express only mutant human APP,
for example, with the Arctic and/or Swedish muta-
tions,5,31 whereas patients are heterozygous for the Arc-
tic mutation or any other APP mutation and, therefore,
produce a mixture of both Awt and Amutant peptides.
The Arctic mutation results in a neuropathologic condition
consisting of cerebral amyloid angiopathy and an abun-
dance of parenchymal A deposits lacking amyloid
cores, and the symptoms are those of typical AD.2 In the
present experiments, a mixture of Awt and AArc in
bitransgenic mice facilitated diffuse A deposition. Re-
cently, in a similar experimental approach, transgenic
models APPDutch and APP23 were cross-bred. The AP-
PDutch model mimics hereditary cerebral hemorrhage
with amyloidosis–Dutch type,32,33 with cerebral amyloid
angiopathy and diffuse A deposits. APP23/APPDutch
mice produced a mixture of Awt and ADutch, and
because A levels were substantially higher in young
APP23 mice than in age-matched APPDutch mice, the
conditions were comparable to those of the present
study. Parenchymal A deposition was reduced in
APP23/APPDutch, and vascular load with microhemor-
rhages was increased, which suggests that ADutch in-
teracted with Awt and altered the pathogenic pheno-
types.34 Thus, direct physical interactions between
AArc/Awt and ADutch/Awt may be relevant patho-
genic mechanisms in patients heterozygous for either of
the mutations, both of which are located in APP at the
same amino acid position. The conditions in human brain
affected with AD unquestionably differ from those of
transgenic mouse brain because N- and C-terminal trun-
cated A that have undergone posttranslational modifi-
cations are far more prevalent in human brain.35,36 In the
transgenic models used, the population of A species
was more homogeneous and dominated by a few types
of A peptides.10 If it is assumed that AArc and Awt
are produced in equimolar amounts in Arctic human
brain, an interesting future experiment would be to cross-
breed mice with equal amounts of AArc and Awt. The
effect, if any, of murine A on extracellular A deposition
is likely small because A pathologic features in APP23
mice with or without the murine APP gene were indistin-
guishable at the light and ultrastructural levels.37 Even
overexpression of murine APP did not alter the extent of
parenchymal A deposition in APPSwe and PS1dE9 mice
(line 85), but did increase the solubility of Awt42 and led
to more cerebral amyloid angiopathy.38 Nonetheless,
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APP-knockout background. In general, considering the
differences to human brain, experiments in transgenic
models must be interpreted cautiously with respect to
patients with AD, for example, those with the Arctic mu-
tation.
Parenchymal A deposits in human brain are classi-
fied according to morphologic features, amyloid tinctorial
characteristics, and neuritic component of the corona.
Whether one plaque type converts to another and, if so,
whether plaque evolution reflects disease progression
have been long-standing questions.39 Diffuse A depos-
its are observed in patients without dementia symptoms
at death and in primates and dogs. They are commonly
assumed to be less pathogenic or even inert, and little is
known about their genesis. Few animal models are rich in
diffuse A deposits. PDAPP mice with a high metabolic
A42 level are an exception.40 It has been suggested
that aggregated A in diffuse plaques form an amyloid
core that becomes surrounded by dystrophic neurites (ie,
emergence of a mature plaque), which are then removed
via phagocytosis, leading to a “burnt out” plaque. The
hypothesis has been challenged in cross-sectional stud-
ies of brains postmortem using IHC and various silver
staining protocols.41 However, the conclusions rest on
the assumption of AD as a homogeneous pathogenic
entity. The strongest experimental evidence for the
“plaque evolution theory” comes from investigations of
patients with Down’s syndrome, who invariably develop
dementia and neuropathologic features of AD due to
trisomy of chromosome 21. Postmortem brains
of different ages have, therefore, been investigated to
understand disease progression. Extracellular diffuse de-
posits of A ending at amino acid 42 (Ax-42) were
observed in 12-year-old children, whereas compact
plaques with A ending at amino acid 40 (Ax-40) were
not evident until age 30 years.42,43 Because diffuse A
deposits predate compact plaques in brains in patients
with Down’s syndrome, it has been thought that with age
they transform into compact plaques. In essence, forma-
tion of an amyloid core is a slow process involving extra-
cellular A accumulation in tissues, followed by structural
modification, isomerization, and truncation of assembled
A peptides. In the present study, accelerated accumu-
lation of diffuse deposits was observed that occurred
independent of compact plaque formation. It was inter-
preted that diffuse and compact plaques can form via
distinct processes, at least in transgenic mice. Consistent
with this hypothesis, rapid formation of compact plaques
has been demonstrated in transgenic models, which are
known to develop few diffuse A deposits.44,45
A begins to accumulate inside neurons.46 The com-
position of intraneuronal A aggregates could depend on
the subcellular location, facilitators (eg, certain lipids or
amyloid-associated factors), and origin (eg, A metabo-
lism in a particular neuronal subtype). Stable A aggre-
gates or A monomers, which have been released from
neurons, would then guide downstream events, leading
to a specific type of extracellular A deposit. The exis-
tence of prion strains illustrates that conformational dif-
ferences can generate distinct pathologic phenotypes.47Axonal transport and synaptic release are clearly in-
volved in extracellular plaque formation.48,49 Thus, dif-
fuse deposits in the striatum of bitransgenic mice were
likely due to corticostriatal connections, resulting in ax-
onal transport of APP/A aggregates and/or extracellular
aggregation after synaptic release of A monomers. No
compact plaques were observed in the striatum, at least
at 18 months of age, again arguing that diffuse and
compact plaques form via different mechanisms.
An important question is whether AArc co-aggregate
with Awt in diffuse deposits or whether they behave
more like enzymes and facilitate a conformational change
in Awt without becoming a part of the final Awt aggre-
gates. The latter idea is reminiscent to that of pathologic
chaperones, heterologous proteins such as ApoE and
1-antichymotrypsin, both of which regulate formation of
A deposits26,27 and are thought to induce or stabilize
the -sheet conformation.50,51 Although both ApoE and
antichymotrypsin stain A deposits, they do not neces-
sarily co-polymerize with A in the fibrils.52 Data from the
present study suggest that AArc behaved as a patho-
logic chaperone; that is, diffuse deposits were not AArc-
immunoreactive. However, because small amounts of
AArc were detected in striatal tissue extracts at ELISA
analysis, that AArc to some extent became building
blocks of the diffuse deposits cannot be ruled out. Hepa-
ran sulfate was found only in compact plaques, possibly
suggesting that they might selectively favor formation of
an amyloid core,28 whereas ApoE and antichymotrypsin
facilitate both diffuse and compact extracellular A de-
position.26,27 Selective association of heparan sulfate
with compact plaques is consistent with previous obser-
vations in brains affected with AD 53 and with the depen-
dence of heparin-binding properties of A on its aggre-
gation state.54 Cross-breeding of bitransgenic mice with
animals in which the biologic characteristics of heparan
sulfate proteoglycans have been manipulated28 would
be needed to further challenge the hypothesis of different
pathways leading to either diffuse A deposits or com-
pact plaques.
Mixtures of AArc/Awt seemed to inhibit fibrillar but
not prefibrillar growth in vitro compared with AArc or
Awt alone, possibly suggesting that the interaction oc-
curred at an early stage. Interpreting differences in ThT
signal in the plateau phase is not straightforward. The
signal should reflect amyloid fibril concentration; how-
ever, it also depends on the number of available binding
sites and the affinity of ThT for those sites in a heteroge-
neous sample, and on quantum yield.55 The percentage
of AArc of total A in aged bitransgenic mice (10%;
Figure 5D) was lower than metabolic AArc levels in
young mice (10% (Figure S5), although AArc alone is
much more prone to aggregate and form amyloid fibrils
than is Awt, both in vitro and in vivo.4,5,13 Apparently, end
products consisting of mixtures of Awt and AArc did
not easily form, perhaps because fibrils have an ordered
structure. As demonstrated by others, A40wt interacted
with A42wt and inhibited fibril formation both in vitro and
in vivo.56,57 Moreover, the efficiency of seeded elongation
of A40wt by Awt40 fibrils was superior to that of
A40wt by A40Arc fibrils in vitro.58 Consistent with this,
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affected fibril structure in vitro and in vivo, as assessed at
p-FTAA spectral analysis and electron microscopy. Oth-
ers have reported that interactions between monomeric
and protofibrillar A interfered with the assembly and
elongation of amyloid fibrils and stabilized A protofi-
brils,59 and the present study detected higher A proto-
fibrillar levels in bitransgenic mice. Heterologous interac-
tions between A variants selectively increased diffuse
A deposits. That is, AArc behaved as a facilitator;
however, in principle, it illustrates that A deposition is
tractable to A fragments or other binders serving as
decelerators.
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